

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Haemolytic uremic syndrome: diagnosis and... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/8-1690/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/8-1690" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Haemolytic uremic syndrome: diagnosis and management" />
    
            <meta name="og:title" content="F1000Research Article: Haemolytic uremic syndrome: diagnosis and management.">
            <meta name="og:description" content="Read the latest article version by Neil S. Sheerin, Emily Glover, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="21904">
            <meta name="article-id" content="19957">
            <meta name="dc.title" content="Haemolytic uremic syndrome: diagnosis and management">
            <meta name="dc.description" content="The thrombotic microangiopathies (TMAs) are a group of diseases characterised by microangiopathic haemolysis, thrombocytopenia, and thrombus formation leading to tissue injury. Traditionally, TMAs have been classified as either thrombotic thrombocytopenic purpura (TTP) or haemolytic uremic syndrome (HUS) based on the clinical presentation, with neurological involvement predominating in the former and acute kidney injury in the latter. However, as our understanding of the pathogenesis of these conditions has increased, it has become clear that this is an over-simplification; there is significant overlap in the clinical presentation of TTP and HUS, there are different forms of HUS, and TMAs can occur in other, diverse clinical scenarios. This review will discuss recent developments in the diagnosis of HUS, focusing on the different forms of HUS and how to diagnose and manage these potentially life-threatening diseases.">
            <meta name="dc.subject" content="Haemolytic Uraemic Syndrome, Thrombotic microangiopathy, Complement">
            <meta name="dc.creator" content="Sheerin, Neil S.">
            <meta name="dc.creator" content="Glover, Emily">
            <meta name="dc.date" content="2019/09/25">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.19957.1">
            <meta name="dc.source" content="F1000Research 2019 8:1690">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Haemolytic Uraemic Syndrome">
            <meta name="prism.keyword" content="Thrombotic microangiopathy">
            <meta name="prism.keyword" content="Complement">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2019/09/25">
            <meta name="prism.volume" content="8">
            <meta name="prism.number" content="1690">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.19957.1">
            <meta name="prism.url" content="https://f1000research.com/articles/8-1690">
            <meta name="citation_title" content="Haemolytic uremic syndrome: diagnosis and management">
            <meta name="citation_abstract" content="The thrombotic microangiopathies (TMAs) are a group of diseases characterised by microangiopathic haemolysis, thrombocytopenia, and thrombus formation leading to tissue injury. Traditionally, TMAs have been classified as either thrombotic thrombocytopenic purpura (TTP) or haemolytic uremic syndrome (HUS) based on the clinical presentation, with neurological involvement predominating in the former and acute kidney injury in the latter. However, as our understanding of the pathogenesis of these conditions has increased, it has become clear that this is an over-simplification; there is significant overlap in the clinical presentation of TTP and HUS, there are different forms of HUS, and TMAs can occur in other, diverse clinical scenarios. This review will discuss recent developments in the diagnosis of HUS, focusing on the different forms of HUS and how to diagnose and manage these potentially life-threatening diseases.">
            <meta name="citation_description" content="The thrombotic microangiopathies (TMAs) are a group of diseases characterised by microangiopathic haemolysis, thrombocytopenia, and thrombus formation leading to tissue injury. Traditionally, TMAs have been classified as either thrombotic thrombocytopenic purpura (TTP) or haemolytic uremic syndrome (HUS) based on the clinical presentation, with neurological involvement predominating in the former and acute kidney injury in the latter. However, as our understanding of the pathogenesis of these conditions has increased, it has become clear that this is an over-simplification; there is significant overlap in the clinical presentation of TTP and HUS, there are different forms of HUS, and TMAs can occur in other, diverse clinical scenarios. This review will discuss recent developments in the diagnosis of HUS, focusing on the different forms of HUS and how to diagnose and manage these potentially life-threatening diseases.">
            <meta name="citation_keywords" content="Haemolytic Uraemic Syndrome, Thrombotic microangiopathy, Complement">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Neil S. Sheerin">
            <meta name="citation_author_institution" content="National Renal Complement Therapeutics Centre, Institute of Cellular Medicine, Newcastle University and Biomedical Research Centre, Newcastle-upon-Tyne NHS Foundation Trust, Newcastle-upon-Tyne, UK">
            <meta name="citation_author" content="Emily Glover">
            <meta name="citation_author_institution" content="National Renal Complement Therapeutics Centre, Institute of Cellular Medicine, Newcastle University and Biomedical Research Centre, Newcastle-upon-Tyne NHS Foundation Trust, Newcastle-upon-Tyne, UK">
            <meta name="citation_publication_date" content="2019/09/25">
            <meta name="citation_volume" content="8">
            <meta name="citation_publication_number" content="1690">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.19957.1">
            <meta name="citation_firstpage" content="1690">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/8-1690/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/8-1690.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=21904 /> <input type=hidden id=articleId name=articleId value=19957 /> <input type=hidden id=xmlUrl value="/articles/8-1690/v1/xml"/> <input type=hidden id=xmlFileName value="-8-1690-v1.xml"> <input type=hidden id=article_uuid value=75be1393-3997-4d5a-a78a-06b4278e6777 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Haemolytic uremic syndrome: diagnosis and management"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.19957.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.19957.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/8-1690"
  },
  "headline": "Haemolytic uremic syndrome: diagnosis and management",
  "datePublished": "2019-09-25T13:30:26",
  "dateModified": "2019-09-25T13:30:26",
  "author": [
    {
      "@type": "Person",
      "name": "Neil S. Sheerin"
    },    {
      "@type": "Person",
      "name": "Emily Glover"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "The thrombotic microangiopathies (TMAs) are a group of diseases characterised by microangiopathic haemolysis, thrombocytopenia, and thrombus formation leading to tissue injury. Traditionally, TMAs have been classified as either thrombotic thrombocytopenic purpura (TTP) or haemolytic uremic syndrome (HUS) based on the clinical presentation, with neurological involvement predominating in the former and acute kidney injury in the latter. However, as our understanding of the pathogenesis of these conditions has increased, it has become clear that this is an over-simplification; there is significant overlap in the clinical presentation of TTP and HUS, there are different forms of HUS, and TMAs can occur in other, diverse clinical scenarios. This review will discuss recent developments in the diagnosis of HUS, focusing on the different forms of HUS and how to diagnose and manage these potentially life-threatening diseases."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/8-1690",
            "name": "Haemolytic uremic syndrome: diagnosis and management"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Haemolytic uremic syndrome: diagnosis and management </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=21904 data-id=19957 data-downloads="" data-views="" data-scholar="10.12688/f1000research.19957.1" data-recommended="" data-doi="10.12688/f1000research.19957.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/8-1690/v1/pdf?article_uuid=75be1393-3997-4d5a-a78a-06b4278e6777" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-19957-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-19957-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-19957-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Sheerin NS and Glover E. Haemolytic uremic syndrome: diagnosis and management [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1690 (<a class=new-orange href="https://doi.org/10.12688/f1000research.19957.1" target=_blank>https://doi.org/10.12688/f1000research.19957.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-19957-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=19957 id=track-article-signin-19957 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/19957?target=/articles/8-1690">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=21904 /> <input name=articleId type=hidden value=19957 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Haemolytic uremic syndrome: diagnosis and management</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:neil.sheerin@ncl.ac.uk" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Neil S. Sheerin</span></a><a href="https://orcid.org/0000-0002-3743-2371" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-3743-2371</div>,&nbsp;</span><span class="">Emily Glover</span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:neil.sheerin@ncl.ac.uk" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Neil S. Sheerin</span></a><a href="http://orcid.org/0000-0002-3743-2371" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-3743-2371</div>,&nbsp;</span><span class="">Emily Glover</span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 25 Sep 2019 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.19957.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> National Renal Complement Therapeutics Centre, Institute of Cellular Medicine, Newcastle University and Biomedical Research Centre, Newcastle-upon-Tyne NHS Foundation Trust, Newcastle-upon-Tyne, UK<br/> <p> <div class=margin-bottom> Neil S. Sheerin <br/> <span>Roles: </span> Writing – Original Draft Preparation </div> <div class=margin-bottom> Emily Glover <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=57330-54342></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=57331-54343></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=57329-54344></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> The thrombotic microangiopathies (TMAs) are a group of diseases characterised by microangiopathic haemolysis, thrombocytopenia, and thrombus formation leading to tissue injury. Traditionally, TMAs have been classified as either thrombotic thrombocytopenic purpura (TTP) or haemolytic uremic syndrome (HUS) based on the clinical presentation, with neurological involvement predominating in the former and acute kidney injury in the latter. However, as our understanding of the pathogenesis of these conditions has increased, it has become clear that this is an over-simplification; there is significant overlap in the clinical presentation of TTP and HUS, there are different forms of HUS, and TMAs can occur in other, diverse clinical scenarios. This review will discuss recent developments in the diagnosis of HUS, focusing on the different forms of HUS and how to diagnose and manage these potentially life-threatening diseases. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Haemolytic Uraemic Syndrome, Thrombotic microangiopathy, Complement </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Neil S. Sheerin (<a href="mailto:neil.sheerin@ncl.ac.uk">neil.sheerin@ncl.ac.uk</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Neil S. Sheerin </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> Neil Sheerin has received sponsorship to attend meetings from Alexion Pharmaceuticals. Emily Glover declares that she has no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2019 Sheerin NS and Glover E. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Sheerin NS and Glover E. Haemolytic uremic syndrome: diagnosis and management [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1690 (<a href="https://doi.org/10.12688/f1000research.19957.1" target=_blank>https://doi.org/10.12688/f1000research.19957.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 25 Sep 2019, <b>8</b>(F1000 Faculty Rev):1690 (<a href="https://doi.org/10.12688/f1000research.19957.1" target=_blank>https://doi.org/10.12688/f1000research.19957.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 25 Sep 2019, <b>8</b>(F1000 Faculty Rev):1690 (<a href="https://doi.org/10.12688/f1000research.19957.1" target=_blank>https://doi.org/10.12688/f1000research.19957.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d8586e142>Introduction</h2><p class="" id=d8586e145>The term thrombotic microangiopathy (TMA) refers to a group of diseases characterised by endothelial dysfunction and the formation of platelet- and fibrin-rich thrombi in small blood vessels. As the thrombus forms, there is consumption of platelets and mechanical disruption of erythrocytes, which leads to the typical haematological manifestations of TMA, thrombocytopenia and microangiopathic haemolytic anaemia (schistocyte [fragment] formation, raised lactate dehydrogenase, and reduced haptoglobin). Previously, the TMAs were classified according to their clinical presentation with neurological symptoms predominating in thrombotic thrombocytopenic purpura (TTP) and acute kidney injury (AKI) in haemolytic uremic syndrome (HUS). However, there is significant overlap in the clinical features of TTP and HUS and the diseases are now classified based on aetiology. TTP is caused by an inherited or acquired (inhibitory autoantibody) defect in ADAMTS13 activity, a circulating protease responsible for the degradation of ultra-large von Willebrand factor multimers. In the absence of ADAMTS13, these multimers accumulate on the surface of endothelial cells, leading to the formation of platelet-rich thrombi.</p><p class="" id=d8586e148>The classification of HUS is more complex, as a pattern of clinical disease consistent with HUS can occur in a wide range of clinical scenarios. Most cases (90%) occur following infection with a Shiga toxin-producing bacteria, either enterohaemorrhagic <i>Escherichia coli</i> (STEC) or <i>Shigella dysenteriae</i>, and typically affect children. The remaining 10% of cases have traditionally been grouped together as atypical HUS. However, as our understanding of the pathogenesis of HUS has increased over the last 20 years, it has become clear that atypical HUS is not one but many different diseases with similar clinical features. A TMA with a pattern of disease consistent with HUS can occur because of inherited disorders, acquired disease states (including malignancy and autoimmune disease), in pregnancy, in severe hypertension, and in response to drugs. The situation is further complicated by the interaction between inherited predisposition to disease and environmental triggers. As a consequence, there is still no universally accepted classification of HUS. In this review, we will, as far as possible, classify HUS according to its aetiology but accept that this may not capture the complexity of the disease pathogenesis.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d8586e160>HUS associated with infection</h2><p class="" id=d8586e163>Infections are the most common cause of HUS. In addition, infection, for example influenza<sup><a href="#ref-1">1</a></sup>, may act indirectly as a trigger for the development of a TMA in patients with a genetic predisposition to disease.</p><div class=section><a name=d8586e170 class=n-a></a><h3 class=section-title>Shiga toxin-induced HUS</h3><p class="" id=d8586e175>HUS associated with infection with a Shiga toxin-producing bacteria (usually STEC HUS) is one of the commonest causes of AKI in children but can occur at any age<sup><a href="#ref-2">2</a></sup>. Although adaptive immune responses can be identified after exposure to enteropathogenic <i>E. coli</i>, it is unclear whether these are protective<sup><a href="#ref-3">3</a></sup>, and the higher rate of infection in children may be due to more frequent exposure. The annual incidence of STEC HUS is approximately 0.7 cases per 100,000 population, with the highest incidence in the summer months. In Europe and North America, <i>E. coli</i> O157 is the serotype most commonly associated with HUS; however, this appears to be changing, with fewer cases of O157-associated HUS and increasing numbers of cases due to other serotypes reported in some countries<sup><a href="#ref-4">4</a></sup>. In parts of Asia, <i>S. dysenteriae</i> type 1 infection is the most common precipitant.</p><p class="" id=d8586e200><b><i>Clinical features</i></b>. Abdominal pain, diarrhoea (bloody in 60%), and vomiting typically occur 3 days after ingestion of bacteria. Approximately 10% of patients exposed to bacteria will then develop HUS. The development of HUS is influenced by both pathogen- (inoculum size, pathogen strain, and type of toxin produced) and host-related factors (microbiome<sup><a href="#ref-5">5</a></sup>, antimotility and antibiotic drug use, inflammatory response, and possible genetic factors<sup><a href="#ref-6">6</a></sup>). In 5–10% of patients with STEC HUS, there will be no preceding history of diarrhoea, highlighting the importance of microbiological investigation of all patients with a TMA irrespective of history<sup><a href="#ref-7">7</a></sup>.</p><p class="" id=d8586e218>Renal involvement is present in most cases and dialysis is required in 50%. Renal recovery after 1–2 weeks is usual, and end-stage renal disease (ESRD) after the initial presentation is uncommon. Neurological involvement is the most frequently reported extra-renal manifestation with seizures and reduced consciousness levels reported in up to one-third of cases<sup><a href="#ref-8">8</a>,<a href="#ref-9">9</a></sup>. Other sites that can be affected include the intestinal tract and pancreas, eyes, and heart. The mortality rate in the acute phase of the disease is approximately 2–5%<sup><a href="#ref-10">10</a></sup> in STEC HUS but is higher when HUS follows <i>Shigella</i> infection<sup><a href="#ref-11">11</a></sup>. Long-term renal sequelae are common, with hypertension and chronic kidney disease (CKD) occurring in 25–40% of patients<sup><a href="#ref-12">12</a>,<a href="#ref-13">13</a></sup>.</p><p class="" id=d8586e246><b><i>Pathogenesis</i></b>. Shiga toxin-producing <i>E. coli</i> can colonise the intestine of healthy animals and can enter the food chain if infected meat or other food products are consumed. Pathogenic <i>E. coli</i> closely associate with the gastrointestinal mucosa and toxin translocates through the epithelium into the circulation where it binds to circulating erythrocytes and leukocytes. The toxin, which comprises one A and five B subunits, binds to globotriaosylceramide (Gb3) on the surface of target cells. It is taken up by endocytosis and is then retrogradely transported to the endoplasmic reticulum<sup><a href="#ref-14">14</a></sup>. The A subunit inhibits protein synthesis, disrupting cell function and ultimately leading to cell death. The toxin also incites an inflammatory response, the net effect being to establish a pro-thrombotic state within the microvasculature<sup><a href="#ref-15">15</a></sup>. The concentration of cell surface Gb3 is particularly high in the kidney, not only on the endothelium but also on podocytes and the tubular epithelium. This may explain the susceptibility of the kidney to injury, but other factors, such as high renal blood flow, may also contribute. Gb3 is also found in other tissues, including the central nervous system, that are affected by STEC HUS.</p><p class="" id=d8586e267><b><i>Diagnosis and management</i></b>. Faecal culture should be performed in all patients with a TMA irrespective of whether there is a history of colitic illness. Diarrhoea may have settled by the time of presentation, but bacteria can still be isolated; therefore, stool or rectal swab should still be sent. PCR can be performed on these samples to detect the presence of Shiga toxin genes. Positive serology for antibodies against toxin-producing <i>E. coli</i> serotypes is supportive of a diagnosis of STEC HUS, although it is not routinely used.</p><p class="" id=d8586e276>Currently, there is no evidence that treatments other than supportive care, including dialysis and ventilator support as required, improve the outcome of patients with STEC HUS. Plasma-based therapy is no longer recommended for the treatment of STEC HUS and may in fact be harmful<sup><a href="#ref-16">16</a></sup>.</p><p class="" id=d8586e283>The role of antibiotics is controversial and their use has traditionally been avoided because of concerns that antibiotic treatment leads to more Shiga toxin release, increasing the likelihood and severity of STEC HUS<sup><a href="#ref-17">17</a></sup>. The effect of antibiotics appears to be both antibiotic and <i>E. coli</i> strain dependent. The β lactams and trimethoprim/sulfamethoxazole have been reported to increase the risk of developing HUS<sup><a href="#ref-17">17</a>–<a href="#ref-19">19</a></sup>. Although fluoroquinolones increase toxin production <i>in vitro</i>, they do not appear to worsen disease. Some antibiotics, such as macrolides and fosfomycin, reduce toxin synthesis and may reduce the risk of HUS<sup><a href="#ref-20">20</a>,<a href="#ref-21">21</a></sup>. When antibiotics are required, they can be used, but the choice of antibiotic should be guided by their potential effect on toxin release. In contrast, antibiotic use in patients with HUS due to <i>Shigella</i> appears to be safe. Trials of toxin-binding resins have failed to show a benefit.</p><p class="" id=d8586e314>A role for complement in the pathogenesis, and therefore a rationale for anti-complement therapies, has been proposed. Preclinical studies in rodent models of STEC HUS have suggested that complement activation is involved in disease development<sup><a href="#ref-22">22</a>–<a href="#ref-24">24</a></sup>; however, animal models of STEC HUS have limitations, and an effect of complement inhibition was not seen in a primate model. In patients with STEC HUS, there is evidence of complement activation<sup><a href="#ref-25">25</a></sup> and C3 levels can be low. In addition, there may be some patients with STEC HUS who also have a defect in complement regulation, and this combination is associated with a poor prognosis<sup><a href="#ref-26">26</a>–<a href="#ref-28">28</a></sup>. These observations have led to the use of eculizumab, a humanised monoclonal antibody raised against complement protein C5, in patients with STEC HUS. There have been reports of patients with STEC HUS, particularly in the presence of severe disease, responding to eculizumab<sup><a href="#ref-29">29</a>,<a href="#ref-30">30</a></sup>. However, STEC HUS is a self-limiting disease and therefore these reports have to be interpreted with caution. The use of eculizumab following the outbreak of STEC HUS in central Europe due to <i>E. coli</i> O104 yielded conflicting reports, with some suggesting benefit<sup><a href="#ref-31">31</a></sup> and others none<sup><a href="#ref-16">16</a></sup>. At present, there is insufficient evidence to support the use of eculizumab in patients with STEC HUS outside of a clinical trial<sup><a href="#ref-32">32</a></sup>. Randomised trials in France (ECULISHU, NCT02205541) and the UK (ECUSTEC, ISRCTN 89553116) are investigating the potential benefit of eculizumab in STEC HUS and will provide much-needed evidence in this area.</p></div><div class=section><a name=d8586e359 class=n-a></a><h3 class=section-title>Pneumococcal HUS</h3><p class="" id=d8586e364>This normally affects children with severe pneumococcal infection, for example pneumonia or empyema, when it complicates approximately 0.5% of cases<sup><a href="#ref-33">33</a></sup>. The exact mechanism of TMA is unknown, but the production of neuraminidase by <i>Pneumococci</i> appears to be important, although other mechanisms have been proposed<sup><a href="#ref-34">34</a></sup>. Neuraminidase strips sialic acid from cell surface glycoproteins, exposing the cryptic Thomsen-Friedenreich (T) antigen, which is recognised by naturally occurring IgM antibodies<sup><a href="#ref-35">35</a></sup>. This leads to the activation of platelets and endothelium, which may be responsible for the TMA and also explains why these patients have a positive Coombs (DAT) test.</p><p class="" id=d8586e382>Pneumococcal pneumonia is the most common preceding infection, but TMA can develop in association with meningitis, empyema, sinusitis, and otitis media. Because of the underlying disease, children are often unwell, with 75% requiring dialysis, and extra-renal manifestations occur frequently<sup><a href="#ref-36">36</a></sup>. The mortality rate is higher than with STEC HUS. Treatment is supportive. The role of plasma exchange is uncertain<sup><a href="#ref-37">37</a></sup>, and, although a response to eculizumab has been reported<sup><a href="#ref-38">38</a>,<a href="#ref-39">39</a></sup>, evidence for its use is limited.</p></div><div class=section><a name=d8586e401 class=n-a></a><h3 class=section-title>HUS occurring in association with other infections</h3><p class="" id=d8586e406>A TMA was a relatively common complication of HIV infection (incidence 2–7%)<sup><a href="#ref-40">40</a></sup> but is seen less frequently following the introduction of highly active anti-retroviral therapy (HAART) (&lt;1%)<sup><a href="#ref-41">41</a></sup>. TMA was associated with high viral load, low CD4 count, and opportunistic infection<sup><a href="#ref-41">41</a></sup> and may be due to a direct effect of the virus on the renal endothelium. Although there have been reports of a response to eculizumab, this is started in combination with HAART and it is therefore difficult to determine which intervention is having the major effect<sup><a href="#ref-42">42</a></sup>. TMA has been associated with a range of other infections (<a href="#T1">Table 1</a>), although for most whether they are a direct cause or a trigger for the TMA remains uncertain.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Infections associated with the development of a thrombotic microangiopathy.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d8586e439 class=n-a></a><thead><a name=d8586e441 class=n-a></a><tr><a name=d8586e443 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d8586e445 class=n-a></a>Shiga toxin-associated diarrhoeal illnesses</th></tr></thead><tbody><a name=d8586e450 class=n-a></a><tr><a name=d8586e452 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d8586e454 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><i>Escherichia coli O157:H7, O26, O80, O91, O103, O104, O111, O121,</i></b><br class=br><b><i>O145</i></b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><i>Shigella dysenteriae type 1</i></b></td></tr><tr><a name=d8586e470 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d8586e472 class=n-a></a>Non-Shiga toxin-associated diarrhoeal illnesses</th></tr><tr><a name=d8586e476 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d8586e478 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Norovirus</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><i>Clostridium difficile</i></b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><i>Campylobacter upsaliensis</i></b></td></tr><tr><a name=d8586e494 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d8586e496 class=n-a></a>Respiratory tract infections</th></tr><tr><a name=d8586e500 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d8586e502 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><i>Streptococcus pneumoniae</i></b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><i>Haemophilus influenzae</i></b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><i>Bordetella pertussis</i></b></td></tr><tr><a name=d8586e520 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d8586e522 class=n-a></a>Other bacterial infections</th></tr><tr><a name=d8586e526 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d8586e528 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><i>Fusobacterium necrophorum</i></b></td></tr><tr><a name=d8586e535 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d8586e537 class=n-a></a>Viral infections</th></tr><tr><a name=d8586e541 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d8586e543 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>HIV</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Cytomegalovirus</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Epstein Barr virus</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Varicella zoster</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Influenza</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Hepatitis A</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Hepatitis C</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Coxsackie B</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Dengue virus</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Human herpes virus 6</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Parvovirus B19</b></td></tr><tr><a name=d8586e591 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d8586e593 class=n-a></a>Parasitic infections</th></tr><tr><a name=d8586e597 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d8586e599 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><i>Plasmodium falciparum</i></b></td></tr></tbody></table></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d8586e613>Atypical HUS</h2><div class=section><a name=d8586e616 class=n-a></a><h3 class=section-title>Complement-mediated atypical HUS</h3><p class="" id=d8586e621>In the 1990s, excessive activation of complement was identified as a cause of atypical HUS<sup><a href="#ref-43">43</a></sup>. An inherited or acquired defect in the control of complement activation can now be found in approximately 60% of cases. In addition, a role for complement activation has been suggested when a TMA occurs in specific clinical scenarios, although the contribution of complement activation in these situations is less clear. In this review, we will consider atypical HUS occurring in the presence of a defined defect in complement regulation as a distinct entity and consider “secondary” TMAs separately.</p><p class="" id=d8586e628><b><i>Clinical features</i></b>. Complement-mediated atypical HUS predominantly affects the kidney, but, as with other forms of HUS, extra-renal manifestations are also seen in approximately 20% of cases, neurological disease being the most common. Older reports suggest a poor prognosis, with up to 50–60% of patients dying or progressing to ESRD within 1 year of presentation. This is influenced by underlying genetic factors, as patients carrying mutations in complement Factor H have a worse prognosis and those with mutations in CD46 have a milder disease.</p><p class="" id=d8586e634><b><i>Pathogenesis</i></b>. The complement system is a complex network of over 40 proteins that constitutes a major part of the innate immune system and contributes to the control of the adaptive immune response. Complement is activated through three distinct pathways (<a href="#f1">Figure 1</a>). The classical pathway is initiated when C1q binds immunoglobulin (IgG and IgM) or other non-immunoglobulin moieties. The lectin pathway is activated when pathogen-associated carbohydrates are recognised by mannose-binding lectin, ficolins, or collectins. The alternative pathway exists in a continuous state of low-level activation in order to respond rapidly to infection but also has an important role in the amplification of the classical and lectin pathways. All pathways converge with proteolytic cleavage of C3, producing C3a and C3b and initiating the terminal complement pathway. This leads to the generation of C5a and assembly of the membrane attack complex, C5b-9, two of the main effectors of complement function. The potential for complement amplification means that tight control is essential to prevent excessive activation, and this is provided by a series of soluble and membrane-bound inhibitors.</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/21904/8471e2d0-c802-4b23-a425-ebf2b3c51a05_figure1.gif"><img alt="8471e2d0-c802-4b23-a425-ebf2b3c51a05_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/21904/8471e2d0-c802-4b23-a425-ebf2b3c51a05_figure1.gif"></a><div class=caption><h3>Figure 1. Activation of the complement cascade.</h3><p id=d8586e653>DAF, decay accelerating factor.</p></div></div><p class="" id=d8586e661>Complement Factor H (CFH) is a fluid-phase complement inhibitor with both decay-accelerating and cofactor activity. Inherited defects in Factor H function were the first complement abnormalities associated with atypical HUS<sup><a href="#ref-43">43</a></sup>. The gene for <i>CFH</i> exists in a gene cluster (Regulators of Complement Activation cluster) along with five highly homologous genes encoding the Factor H-related proteins (<i>CFHR1–5</i>). It is now known that mutations, deletions, and genomic rearrangements are common in this region and variants in <i>CFH</i> are the most common disease-causing variants (20–30%)<sup><a href="#ref-44">44</a>–<a href="#ref-46">46</a></sup>. Mutations in the serine protease Factor I (5–10% of cases)<sup><a href="#ref-47">47</a>,<a href="#ref-48">48</a></sup> and Membrane Cofactor Protein (MCP, CD46, 10% of cases)<sup><a href="#ref-49">49</a>,<a href="#ref-50">50</a></sup> are also associated with disease. In addition, an acquired defect in complement control due to autoantibodies against Factor H, usually associated with homozygotic deletion of <i>CFHR1–3</i>, can also cause atypical HUS<sup><a href="#ref-51">51</a>,<a href="#ref-52">52</a></sup>, as can gain-of-function mutations in proteins involved in the activation of complement, including variants in C3 (5% of cases)<sup><a href="#ref-53">53</a></sup> and rarely Factor B<sup><a href="#ref-54">54</a></sup>. Distinguishing disease-causing mutations from variants of uncertain significance or benign polymorphisms is complex and requires the combination of expert knowledge and application of international standards<sup><a href="#ref-55">55</a></sup>. Not all patients who carry a mutation develop disease, perhaps 50–60%, with commonly occurring genetic polymorphisms in <i>CFH</i> and <i>CD46</i><sup><a href="#ref-56">56</a></sup> modifying this risk and an environmental trigger required to precipitate disease.</p><p class="" id=d8586e731><b><i>Diagnosis and management</i></b>. Diagnosis is primarily clinical and based on the exclusion of other possible causes of TMA, particularly TTP and STEC infection. C3 can be low in this patient group, but a normal C3 level does not exclude complement-mediated atypical HUS. Genetic screening, assessment for the presence of autoantibodies, and neutrophil surface CD46 levels should be performed in all patients. However, these results, particularly genetic analysis, are not immediately available and therefore do not guide initial diagnosis and early treatment choices.</p><p class="" id=d8586e737>Plasma exchange was the standard treatment and is still first line until TTP has been excluded (preserved ADAMTS13 activity). Once TTP has been excluded, eculizumab is currently the optimal treatment, but because of its high price this is not available in all countries and plasma exchange is still used. Eculizumab is a highly effective treatment for complement-mediated atypical HUS, establishing remission in &gt;85% of cases<sup><a href="#ref-57">57</a></sup> with a significant improvement in renal outcomes<sup><a href="#ref-58">58</a></sup>. The current licence for eculizumab recommends continued treatment because of the risk of relapse. However, several series have now reported withdrawal of eculizumab in patients with complement-mediated disease, with the risk of relapse particularly low in those patients without a mutation<sup><a href="#ref-59">59</a>–<a href="#ref-61">61</a></sup>. There is a risk of relapse, particularly in patients with Factor H mutations, but re-introduction of eculizumab rapidly re-establishes remission. The use of complement inhibition to induce remission and intermittently treat relapse may be a future strategy to manage disease that would reduce the treatment burden, cost, and infection risk associated with continuous treatment. As the liver is the main site of complement protein synthesis (with the exception of CD46), liver transplantation has been proposed as a cure for genetic causes of complement-mediated atypical HUS, particularly in those patients who also require a kidney transplant<sup><a href="#ref-62">62</a></sup>. With the availability of eculizumab, this option is used less frequently.</p><p class="" id=d8586e759>For patients with complement-mediated atypical HUS who develop ESRD, there is high risk (80–90%) of recurrent disease following transplantation<sup><a href="#ref-63">63</a>,<a href="#ref-64">64</a></sup>. This is true for all genetic and acquired causes of aHUS with the exception of patients who have a mutation in <i>CD46</i>, which, because it is expressed on the renal transplant endothelium, has normal function in the transplant kidney. Disease can recur in patients in whom no defect in complement regulation is found, although the risk is lower (30%)<sup><a href="#ref-65">65</a></sup>. Recurrence usually occurs early (within 3–6 months) and is associated with a high risk of graft loss<sup><a href="#ref-64">64</a></sup>. With the availability of eculizumab, patients can now be successfully transplanted, with options to use eculizumab to treat disease recurrence or prophylactically to prevent recurrence<sup><a href="#ref-66">66</a></sup>.</p></div><div class=section><a name=d8586e785 class=n-a></a><h3 class=section-title>Other inherited disorders associated with atypical HUS</h3><p class="" id=d8586e790>Homozygous or compound heterozygous mutations in diacylglycerol kinase ε can lead to atypical HUS<sup><a href="#ref-67">67</a></sup>. The mechanism by which this lipid kinase leads to a TMA is unknown, but a number of possible mechanisms have been suggested, including release of pro-thrombotic factors, platelet activation, and changes in vascular tone. Patients usually present in childhood, significant proteinuria is common, there may be histological features of membranoproliferative glomerulonephritis<sup><a href="#ref-68">68</a></sup>, and the disease may follow a relapsing–remitting course<sup><a href="#ref-69">69</a></sup>. Patients commonly progress to CKD and ESRD, at which stage transplant is an option, as disease recurrence has not been reported<sup><a href="#ref-69">69</a></sup>. There is no effective treatment and, as complement is not involved in disease development<sup><a href="#ref-70">70</a></sup>, eculizumab does not control disease<sup><a href="#ref-67">67</a>,<a href="#ref-69">69</a></sup>.</p><p class="" id=d8586e821>Methylmalonic aciduria and homocystinuria type C protein is involved in the metabolism of vitamin B12 (cobalamin). Homozygotic or compound heterozygotic mutations in the gene encoding this protein, <i>MMACHC</i> (cobalamin C [cblC] defect), causes an atypical HUS-like disease<sup><a href="#ref-71">71</a></sup> in addition to a wide range of other clinical features including neurological, cardiac, and pulmonary abnormalities (particularly pulmonary hypertension)<sup><a href="#ref-72">72</a></sup>. Biochemically, patients have elevated plasma homocysteine, low methionine, and methylmalonic aciduria. Biochemical and genetic analysis is vital in patients presenting with a TMA, particularly if there are other clinical abnormalities. Patients usually present in childhood, and without treatment the prognosis is poor, with a 100% mortality reported without treatment<sup><a href="#ref-72">72</a></sup>. Patients respond to treatment with hydroxocobalamin (B12) and betaine, and treatment can be initiated before the results of biochemical and genetic analyses are available<sup><a href="#ref-73">73</a></sup>. Complement is unlikely to have a role in this disease, and experience suggests that eculizumab is ineffective<sup><a href="#ref-74">74</a></sup>.</p><p class="" id=d8586e848>Genetic variants in thrombomodulin (<i>THBD</i>) have been reported in patients with atypical HUS<sup><a href="#ref-75">75</a></sup>. Thrombomodulin is part of the coagulation pathway and enhances thrombus formation. It may also activate complement and possibly links these two pathways. New genes associated with atypical HUS are being identified, for example <i>INF2</i><sup><a href="#ref-76">76</a></sup>, which may provide insights into the pathophysiology of TMA as well as explain the disease in some patients in whom no complement defect is identified.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d8586e868>Atypical HUS occurring in specific clinical scenarios</h2><p class="" id=d8586e871>A TMA can develop in a range of different scenarios and, whilst in some cases, as in pregnancy-associated TMA, patients may have a defect in complement regulation, in most cases no abnormality will be found<sup><a href="#ref-77">77</a></sup>.</p><div class=section><a name=d8586e878 class=n-a></a><h3 class=section-title>Pregnancy-associated TMA</h3><p class="" id=d8586e883>There are a number of causes of a TMA either during pregnancy or in the post-partum period, including pre-eclampsia, HELLP syndrome, TTP, and atypical HUS. Differentiating among these can be difficult and is reviewed elsewhere<sup><a href="#ref-78">78</a></sup>. Approximately 20% of cases of atypical HUS occur in association with pregnancy, and these most commonly occur in the post-partum period<sup><a href="#ref-79">79</a></sup>. A significant proportion of women developing atypical HUS in association with pregnancy have a genetic defect in a complement regulator, suggesting pregnancy is the trigger for disease in women with a genetic predisposition<sup><a href="#ref-79">79</a>,<a href="#ref-80">80</a></sup>. These observations have led to the use of eculizumab in pregnancy-associated HUS with reports of good outcomes<sup><a href="#ref-81">81</a></sup>, although no trial data are available.</p></div><div class=section><a name=d8586e906 class=n-a></a><h3 class=section-title>TMA associated with severe hypertension</h3><p class="" id=d8586e911>Severe hypertension causing a TMA and atypical HUS due to an inherited defect in complement regulation can present with identical clinical features. Pre-existing hypertension, particularly if poorly controlled, and other features of hypertensive end organ damage make a secondary TMA more likely. However, if there is no improvement in laboratory parameters with control of blood pressure, treatment with eculizumab should be considered at least until genetic analysis is available. This strategy avoids missing patients with a defect in complement regulation rather than suggesting that hypertension-mediated TMA will respond to complement inhibition<sup><a href="#ref-82">82</a></sup>.</p></div><div class=section><a name=d8586e919 class=n-a></a><h3 class=section-title>Drug-related TMA</h3><p class="" id=d8586e924>The development of a TMA has been reported in association with the use of a range of drugs including those used in the treatment of cancer<sup><a href="#ref-83">83</a></sup>, immunomodulators, and anti-platelet drugs (<a href="#T2">Table 2</a>). For some drugs, this appears to be a direct effect on the endothelium, as is the case for interferon-β<sup><a href="#ref-84">84</a></sup> and bevacizumab<sup><a href="#ref-85">85</a></sup>, whilst in the case of quinine the TMA is due to the development of autoantibodies against platelet glycoproteins. The TMA induced by clopidogrel<sup><a href="#ref-86">86</a></sup> and ticlopidine<sup><a href="#ref-87">87</a></sup> leads to the production of antibodies against ADAMTS13 and a TTP-like disease that responds to plasma exchange. In most cases, the exact mechanism of TMA development is unknown and management is supportive with withdrawal of the causative drug.</p><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. Drugs implicated in the development of a thrombotic microangiopathy.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d8586e962 class=n-a></a><thead><a name=d8586e964 class=n-a></a><tr><a name=d8586e966 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d8586e968 class=n-a></a>Chemotherapy drugs</th></tr></thead><tbody><a name=d8586e973 class=n-a></a><tr><a name=d8586e975 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d8586e977 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Cisplatin</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Mitomycin</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Gemcitabine</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Vincristine</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Oxaliplatin</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Pentostatin</b></td></tr><tr><a name=d8586e1004 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d8586e1006 class=n-a></a>Anti-platelet drugs</th></tr><tr><a name=d8586e1010 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d8586e1012 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Clopidogrel</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Ticlopidine</b></td></tr><tr><a name=d8586e1022 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d8586e1024 class=n-a></a>Vascular endothelial growth factor inhibitors</th></tr><tr><a name=d8586e1028 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d8586e1030 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Bevacizumab</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Ramucirumab</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Aflibercept</b></td></tr><tr><a name=d8586e1045 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d8586e1047 class=n-a></a>Immunosuppressive drugs</th></tr><tr><a name=d8586e1051 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d8586e1053 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Ciclosporin</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Tacrolimus</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Sirolimus</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Everolimus</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Alemtuzumab (Campath)</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Muromonab-CD3</b></td></tr><tr><a name=d8586e1080 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d8586e1082 class=n-a></a>Interferons</th></tr><tr><a name=d8586e1086 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d8586e1088 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Interferon-α</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Interferon-β</b></td></tr><tr><a name=d8586e1098 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d8586e1100 class=n-a></a>Tyrosine kinase inhibitors</th></tr><tr><a name=d8586e1104 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d8586e1106 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Sunitinib</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Sorafenib</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Cediranib</b></td></tr><tr><a name=d8586e1121 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d8586e1123 class=n-a></a>Antibiotics</th></tr><tr><a name=d8586e1127 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d8586e1129 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Penicillin</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Ciprofloxacin</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Sulfisoxazole</b></td></tr><tr><a name=d8586e1143 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d8586e1145 class=n-a></a>Illicit drugs</th></tr><tr><a name=d8586e1149 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d8586e1151 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Cocaine</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Heroin</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Ecstasy</b></td></tr><tr><a name=d8586e1165 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d8586e1167 class=n-a></a>Miscellaneous drugs</th></tr><tr><a name=d8586e1171 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d8586e1173 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Oral contraceptive pill</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Quetiapine</b></td></tr></tbody></table></div></div><div class=section><a name=d8586e1188 class=n-a></a><h3 class=section-title>Malignancy-related TMA</h3><p class="" id=d8586e1193>TMAs can occur in a wide range of malignancies including stomach, breast, and bowel cancer and haematological malignancy<sup><a href="#ref-88">88</a></sup>. The exact mechanism of disease is unknown, but microvascular metastases may initiate the TMA. In some patients, it may be difficult to differentiate between a TMA caused by the malignancy or due to the chemotherapy used in its treatment.</p></div><div class=section><a name=d8586e1201 class=n-a></a><h3 class=section-title>Post bone marrow transplant TMA</h3><p class="" id=d8586e1206>The development of a TMA has been reported in 10–40% of patients following allogeneic bone marrow transplantation. There are several factors that could contribute to this, including the graft-versus-host response, calcineurin inhibitors, chemotherapy, and infection. Defects in complement regulation have also been reported<sup><a href="#ref-89">89</a></sup>, and there is evidence for complement activation (increased soluble C5b-9) in some cases. These observations have led to the use of eculizumab in this situation<sup><a href="#ref-90">90</a>,<a href="#ref-91">91</a></sup>, although evidence that this should be part of the management of this condition is still lacking.</p></div><div class=section><a name=d8586e1221 class=n-a></a><h3 class=section-title>TMA following solid organ transplantation</h3><p class="" id=d8586e1226>A TMA can occur after any solid organ transplant, most frequently kidney transplantation, and is due to a number of factors including calcineurin inhibitor toxicity, ischaemia reperfusion injury, antibody-mediated rejection, and infection. Complement mutations have been reported, in up to 30% from one series<sup><a href="#ref-92">92</a></sup>, possibly due to recurrence of previously undiagnosed atypical HUS. Complement inhibition should be considered, particularly if there is uncertainty about primary diagnosis or the TMA does not resolve with measures such as calcineurin inhibitor withdrawal.</p></div><div class=section><a name=d8586e1234 class=n-a></a><h3 class=section-title>TMA occurring in patients with autoimmune disease</h3><p class="" id=d8586e1239>The presence of a TMA has been reported in association with a range of primary glomerular diseases, for example, IgA nephropathy, ANCA-associated vasculitis, and FSGS. Patients with C3 glomerulopathy, a disease also characterised by complement dysregulation, may also develop a TMA<sup><a href="#ref-93">93</a></sup>. A TMA can also develop in lupus nephritis and in patients with antiphospholipid syndrome (APS), particularly catastrophic APS. Complement is activated in both of these diseases and a role for eculizumab has been reported<sup><a href="#ref-94">94</a></sup>, but evidence from clinical trials is not available. A TMA can also be seen in patients with scleroderma renal crisis.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d8586e1254>Concluding remarks</h2><p class="" id=d8586e1257>HUS can develop in response to a number of different triggers and in a variety of clinical situations. Identifying the cause of HUS can be difficult but is critical, as the treatment and prognosis is dependent on accurate and timely diagnosis.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d8586e1264 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d9223>References</h2><div class="section ref-list"><a name=d8586e1264 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d8586e1271 class=n-a></a>Bitzan M, Zieg J: Influenza-associated thrombotic microangiopathies. <i>Pediatr Nephrol.</i> 2018; <b>33</b>(11): 2009–2025. <a target=xrefwindow id=d8586e1279 href="http://www.ncbi.nlm.nih.gov/pubmed/28884355">PubMed Abstract </a> | <a target=xrefwindow id=d8586e1282 href="https://doi.org/10.1007/s00467-017-3783-4">Publisher Full Text </a> | <a target=xrefwindow id=d8586e1285 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6153504">Free Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d8586e1294 class=n-a></a>Tarr PI, Gordon CA, Chandler WL: Shiga-toxin-producing <i>Escherichia coli</i> and haemolytic uraemic syndrome. <i>Lancet.</i> 2005; <b>365</b>(9464): 1073–86. <a target=xrefwindow id=d8586e1305 href="http://www.ncbi.nlm.nih.gov/pubmed/15781103">PubMed Abstract </a> | <a target=xrefwindow id=d8586e1308 href="https://doi.org/10.1016/S0140-6736(05)71144-2">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d8586e1317 class=n-a></a>Jenkins C, Chart H, Smith HR, <i> et al.</i>: Antibody response of patients infected with verocytotoxin-producing <i>Escherichia coli</i> to protein antigens encoded on the <i>LEE</i> locus. <i>J Med Microbiol.</i> 2000; <b>49</b>(1): 97–101. <a target=xrefwindow id=d8586e1335 href="http://www.ncbi.nlm.nih.gov/pubmed/10628831">PubMed Abstract </a> | <a target=xrefwindow id=d8586e1338 href="https://doi.org/10.1099/0022-2615-49-1-97">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735174634"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8586e1347 class=n-a></a>Bruyand M, Mariani-Kurkdjian P, Le Hello S, <i> et al.</i>: Paediatric haemolytic uraemic syndrome related to Shiga toxin-producing <i>Escherichia coli</i>, an overview of 10 years of surveillance in France, 2007 to 2016. <i>Euro Surveill.</i> 2019; <b>24</b>(8):1800068. <a target=xrefwindow id=d8586e1361 href="http://www.ncbi.nlm.nih.gov/pubmed/30808442">PubMed Abstract </a> | <a target=xrefwindow id=d8586e1365 href="https://doi.org/10.2807/1560-7917.ES.2019.24.8.1800068">Publisher Full Text </a> | <a target=xrefwindow id=d8586e1368 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6446949">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735174634">F1000 Recommendation</a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d8586e1381 class=n-a></a>Pifer R, Sperandio V: The Interplay between the Microbiota and Enterohemorrhagic <i>Escherichia coli</i>. <i>Microbiol Spectr.</i> 2014; <b>2</b>(5). <a target=xrefwindow id=d8586e1392 href="http://www.ncbi.nlm.nih.gov/pubmed/26104352">PubMed Abstract </a> | <a target=xrefwindow id=d8586e1395 href="https://doi.org/10.1128/microbiolspec.EHEC-0015-2013">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d8586e1405 class=n-a></a>Karmali MA: Host and pathogen determinants of verocytotoxin-producing <i>Escherichia coli</i>-associated hemolytic uremic syndrome. <i>Kidney Int Suppl.</i> 2009; <b>75</b>(Supplement 112): S4–7. <a target=xrefwindow id=d8586e1416 href="http://www.ncbi.nlm.nih.gov/pubmed/19180132">PubMed Abstract </a> | <a target=xrefwindow id=d8586e1419 href="https://doi.org/10.1038/ki.2008.608">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d8586e1428 class=n-a></a>Brandt JR, Fouser LS, Watkins SL, <i> et al.</i>: <i>Escherichia coli</i> O 157:H7-associated hemolytic-uremic syndrome after ingestion of contaminated hamburgers. <i>J Pediatr.</i> 1994; <b>125</b>(4): 519–26. <a target=xrefwindow id=d8586e1442 href="http://www.ncbi.nlm.nih.gov/pubmed/7931869">PubMed Abstract </a> | <a target=xrefwindow id=d8586e1446 href="https://doi.org/10.1016/s0022-3476(94)70002-8">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d8586e1455 class=n-a></a>Hahn JS, Havens PL, Higgins JJ, <i> et al.</i>: Neurological complications of hemolytic-uremic syndrome. <i>J Child Neurol.</i> 1989; <b>4</b>(2): 108–13. <a target=xrefwindow id=d8586e1466 href="http://www.ncbi.nlm.nih.gov/pubmed/2715605">PubMed Abstract </a> | <a target=xrefwindow id=d8586e1469 href="https://doi.org/10.1177/088307388900400206">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d8586e1478 class=n-a></a>Sheth KJ, Swick HM, Haworth N: Neurological involvement in hemolytic-uremic syndrome. <i>Ann Neurol.</i> 1986; <b>19</b>(1): 90–3. <a target=xrefwindow id=d8586e1486 href="http://www.ncbi.nlm.nih.gov/pubmed/3947042">PubMed Abstract </a> | <a target=xrefwindow id=d8586e1489 href="https://doi.org/10.1002/ana.410190120">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d8586e1498 class=n-a></a>Majowicz SE, Scallan E, Jones-Bitton A, <i> et al.</i>: Global incidence of human Shiga toxin-producing <i>Escherichia coli</i> infections and deaths: a systematic review and knowledge synthesis. <i>Foodborne Pathog Dis.</i> 2014; <b>11</b>(6): 447–55. <a target=xrefwindow id=d8586e1512 href="http://www.ncbi.nlm.nih.gov/pubmed/24750096">PubMed Abstract </a> | <a target=xrefwindow id=d8586e1516 href="https://doi.org/10.1089/fpd.2013.1704">Publisher Full Text </a> | <a target=xrefwindow id=d8586e1519 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4607253">Free Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d8586e1528 class=n-a></a>Butler T: Haemolytic uraemic syndrome during shigellosis. <i>Trans R Soc Trop Med Hyg.</i> 2012; <b>106</b>(7): 395–9. <a target=xrefwindow id=d8586e1536 href="http://www.ncbi.nlm.nih.gov/pubmed/22579556">PubMed Abstract </a> | <a target=xrefwindow id=d8586e1539 href="https://doi.org/10.1016/j.trstmh.2012.04.001">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d8586e1549 class=n-a></a>Spinale JM, Ruebner RL, Copelovitch L, <i> et al.</i>: Long-term outcomes of Shiga toxin hemolytic uremic syndrome. <i>Pediatr Nephrol.</i> 2013; <b>28</b>(11): 2097–105. <a target=xrefwindow id=d8586e1560 href="http://www.ncbi.nlm.nih.gov/pubmed/23288350">PubMed Abstract </a> | <a target=xrefwindow id=d8586e1563 href="https://doi.org/10.1007/s00467-012-2383-6">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d8586e1572 class=n-a></a>Garg AX, Suri RS, Barrowman N, <i> et al.</i>: Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. <i>JAMA.</i> 2003; <b>290</b>(10): 1360–70. <a target=xrefwindow id=d8586e1583 href="http://www.ncbi.nlm.nih.gov/pubmed/12966129">PubMed Abstract </a> | <a target=xrefwindow id=d8586e1586 href="https://doi.org/10.1001/jama.290.10.1360">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d8586e1595 class=n-a></a>Sandvig K, Bergan J, Dyve AB, <i> et al.</i>: Endocytosis and retrograde transport of Shiga toxin. <i>Toxicon.</i> 2010; <b>56</b>(7): 1181–5. <a target=xrefwindow id=d8586e1606 href="http://www.ncbi.nlm.nih.gov/pubmed/19951719">PubMed Abstract </a> | <a target=xrefwindow id=d8586e1609 href="https://doi.org/10.1016/j.toxicon.2009.11.021">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d8586e1618 class=n-a></a>Obrig TG: <i>Escherichia coli</i> Shiga Toxin Mechanisms of Action in Renal Disease. <i>Toxins (Basel).</i> 2010; <b>2</b>(12): 2769–94. <a target=xrefwindow id=d8586e1629 href="http://www.ncbi.nlm.nih.gov/pubmed/21297888">PubMed Abstract </a> | <a target=xrefwindow id=d8586e1632 href="https://doi.org/10.3390/toxins2122769">Publisher Full Text </a> | <a target=xrefwindow id=d8586e1636 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3032420">Free Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718131010"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8586e1645 class=n-a></a>Menne J, Nitschke M, Stingele R, <i> et al.</i>: Validation of treatment strategies for enterohaemorrhagic <i>Escherichia coli</i> O104:H4 induced haemolytic uraemic syndrome: case-control study. <i>BMJ.</i> 2012; <b>345</b>: e4565. <a target=xrefwindow id=d8586e1659 href="http://www.ncbi.nlm.nih.gov/pubmed/22815429">PubMed Abstract </a> | <a target=xrefwindow id=d8586e1663 href="https://doi.org/10.1136/bmj.e4565">Publisher Full Text </a> | <a target=xrefwindow id=d8586e1666 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3400392">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718131010">F1000 Recommendation</a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717952621"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8586e1679 class=n-a></a>Wong CS, Mooney JC, Brandt JR, <i> et al.</i>: Risk factors for the hemolytic uremic syndrome in children infected with <i>Escherichia coli</i> O157:H7: a multivariable analysis. <i>Clin Infect Dis.</i> 2012; <b>55</b>(1): 33–41. <a target=xrefwindow id=d8586e1693 href="http://www.ncbi.nlm.nih.gov/pubmed/22431799">PubMed Abstract </a> | <a target=xrefwindow id=d8586e1697 href="https://doi.org/10.1093/cid/cis299">Publisher Full Text </a> | <a target=xrefwindow id=d8586e1700 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3493180">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717952621">F1000 Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d8586e1714 class=n-a></a>Launders N, Byrne L, Jenkins C, <i> et al.</i>: Disease severity of Shiga toxin-producing <i>E. coli</i> O157 and factors influencing the development of typical haemolytic uraemic syndrome: a retrospective cohort study, 2009-2012. <i>BMJ Open.</i> 2016; <b>6</b>(1): e009933. <a target=xrefwindow id=d8586e1728 href="http://www.ncbi.nlm.nih.gov/pubmed/26826153">PubMed Abstract </a> | <a target=xrefwindow id=d8586e1732 href="https://doi.org/10.1136/bmjopen-2015-009933">Publisher Full Text </a> | <a target=xrefwindow id=d8586e1735 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4735319">Free Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d8586e1744 class=n-a></a>Wong CS, Jelacic S, Habeeb RL, <i> et al.</i>: The risk of the hemolytic-uremic syndrome after antibiotic treatment of <i>Escherichia coli</i> O157:H7 infections. <i>N Engl J Med.</i> 2000; <b>342</b>(26): 1930–6. <a target=xrefwindow id=d8586e1758 href="http://www.ncbi.nlm.nih.gov/pubmed/10874060">PubMed Abstract </a> | <a target=xrefwindow id=d8586e1762 href="https://doi.org/10.1056/NEJM200006293422601">Publisher Full Text </a> | <a target=xrefwindow id=d8586e1765 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3659814">Free Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735894289"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8586e1774 class=n-a></a>Kakoullis L, Papachristodoulou E, Chra P, <i> et al.</i>: Shiga toxin-induced haemolytic uraemic syndrome and the role of antibiotics: a global overview. <i>J Infect.</i> 2019; <b>79</b>(2): 75–94. <a target=xrefwindow id=d8586e1785 href="http://www.ncbi.nlm.nih.gov/pubmed/31150744">PubMed Abstract </a> | <a target=xrefwindow id=d8586e1788 href="https://doi.org/10.1016/j.jinf.2019.05.018">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735894289">F1000 Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/723496466"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8586e1801 class=n-a></a>Safdar N, Said A, Gangnon RE, <i> et al.</i>: Risk of hemolytic uremic syndrome after antibiotic treatment of <i>Escherichia coli</i> O157:H7 enteritis: a meta-analysis. <i>JAMA.</i> 2002; <b>288</b>(8): 996–1001. <a target=xrefwindow id=d8586e1815 href="http://www.ncbi.nlm.nih.gov/pubmed/12190370">PubMed Abstract </a> | <a target=xrefwindow id=d8586e1819 href="https://doi.org/10.1001/jama.288.8.996">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/723496466">F1000 Recommendation</a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d8586e1832 class=n-a></a>Morigi M, Galbusera M, Gastoldi S, <i> et al.</i>: Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. <i>J Immunol.</i> 2011; <b>187</b>(1): 172–80. <a target=xrefwindow id=d8586e1843 href="http://www.ncbi.nlm.nih.gov/pubmed/21642543">PubMed Abstract </a> | <a target=xrefwindow id=d8586e1846 href="https://doi.org/10.4049/jimmunol.1100491">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d8586e1855 class=n-a></a>Arvidsson I, Rebetz J, Loos S, <i> et al.</i>: Early Terminal Complement Blockade and C6 Deficiency Are Protective in Enterohemorrhagic <i>Escherichia coli</i>-Infected Mice. <i>J Immunol.</i> 2016; <b>197</b>(4): 1276–86. <a target=xrefwindow id=d8586e1869 href="http://www.ncbi.nlm.nih.gov/pubmed/27421478">PubMed Abstract </a> | <a target=xrefwindow id=d8586e1873 href="https://doi.org/10.4049/jimmunol.1502377">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d8586e1883 class=n-a></a>Ozaki M, Kang Y, Tan YS, <i> et al.</i>: Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury. <i>Kidney Int.</i> 2016; <b>90</b>(4): 774–82. <a target=xrefwindow id=d8586e1894 href="http://www.ncbi.nlm.nih.gov/pubmed/27378476">PubMed Abstract </a> | <a target=xrefwindow id=d8586e1897 href="https://doi.org/10.1016/j.kint.2016.05.011">Publisher Full Text </a> | <a target=xrefwindow id=d8586e1901 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5026569">Free Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d8586e1910 class=n-a></a>Thurman JM, Marians R, Emlen W, <i> et al.</i>: Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. <i>Clin J Am Soc Nephrol.</i> 2009; <b>4</b>(12): 1920–4. <a target=xrefwindow id=d8586e1921 href="http://www.ncbi.nlm.nih.gov/pubmed/19820137">PubMed Abstract </a> | <a target=xrefwindow id=d8586e1924 href="https://doi.org/10.2215/CJN.02730409">Publisher Full Text </a> | <a target=xrefwindow id=d8586e1928 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2798880">Free Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d8586e1937 class=n-a></a>Dowen F, Wood K, Brown AL, <i> et al.</i>: Rare genetic variants in Shiga toxin-associated haemolytic uraemic syndrome: genetic analysis prior to transplantation is essential. <i>Clinical Kidney J.</i> 2017; <b>10</b>(4): 490–493. <a target=xrefwindow id=d8586e1948 href="http://www.ncbi.nlm.nih.gov/pubmed/28852487">PubMed Abstract </a> | <a target=xrefwindow id=d8586e1951 href="https://doi.org/10.1093/ckj/sfx030">Publisher Full Text </a> | <a target=xrefwindow id=d8586e1955 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5569917">Free Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d8586e1964 class=n-a></a>Alberti M, Valoti E, Piras R, <i> et al.</i>: Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations. <i>Am J Transplant.</i> 2013; <b>13</b>(8): 2201–6. <a target=xrefwindow id=d8586e1975 href="http://www.ncbi.nlm.nih.gov/pubmed/23731345">PubMed Abstract </a> | <a target=xrefwindow id=d8586e1978 href="https://doi.org/10.1111/ajt.12297">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d8586e1987 class=n-a></a>Frémeaux-Bacchi V, Sellier-Leclerc AL, Vieira-Martins P, <i> et al.</i>: Complement Gene Variants and Shiga Toxin-Producing <i>Escherichia coli</i>-Associated Hemolytic Uremic Syndrome: Retrospective Genetic and Clinical Study. <i>Clin J Am Soc Nephrol.</i> 2019; <b>14</b>(3): 364–377. <a target=xrefwindow id=d8586e2001 href="http://www.ncbi.nlm.nih.gov/pubmed/30674459">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2005 href="https://doi.org/10.2215/CJN.05830518">Publisher Full Text </a> | <a target=xrefwindow id=d8586e2008 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6419292">Free Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d8586e2017 class=n-a></a>Lapeyraque AL, Malina M, Fremeaux-Bacchi V, <i> et al.</i>: Eculizumab in severe Shiga-toxin-associated HUS. <i>N Engl J Med.</i> 2011; <b>364</b>(26): 2561–3. <a target=xrefwindow id=d8586e2028 href="http://www.ncbi.nlm.nih.gov/pubmed/21612462">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2031 href="https://doi.org/10.1056/NEJMc1100859">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d8586e2041 class=n-a></a>Pape L, Hartmann H, Bange FC, <i> et al.</i>: Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement. <i>Medicine (Baltimore).</i> 2015; <b>94</b>(24): e1000. <a target=xrefwindow id=d8586e2052 href="http://www.ncbi.nlm.nih.gov/pubmed/26091445">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2055 href="https://doi.org/10.1097/MD.0000000000001000">Publisher Full Text </a> | <a target=xrefwindow id=d8586e2059 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4616562">Free Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d8586e2068 class=n-a></a>Delmas Y, Vendrely B, Clouzeau B, <i> et al.</i>: Outbreak of <i>Escherichia coli</i> O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab. <i>Nephrol Dial Transplant.</i> 2014; <b>29</b>(3): 565–72. <a target=xrefwindow id=d8586e2082 href="http://www.ncbi.nlm.nih.gov/pubmed/24293658">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2086 href="https://doi.org/10.1093/ndt/gft470">Publisher Full Text </a> | <a target=xrefwindow id=d8586e2089 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3938298">Free Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732381254"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8586e2098 class=n-a></a>Keenswijk W, Raes A, Vande Walle J: Is eculizumab efficacious in Shigatoxin-associated hemolytic uremic syndrome? A narrative review of current evidence. <i>Eur J Pediatr.</i> 2018; <b>177</b>(3): 311–8. <a target=xrefwindow id=d8586e2106 href="http://www.ncbi.nlm.nih.gov/pubmed/29288280">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2109 href="https://doi.org/10.1007/s00431-017-3077-7">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732381254">F1000 Recommendation</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d8586e2122 class=n-a></a>Spinale JM, Ruebner RL, Kaplan BS, <i> et al.</i>: Update on <i>Streptococcus pneumoniae</i> associated hemolytic uremic syndrome. <i>Curr Opin Pediatr.</i> 2013; <b>25</b>(2): 203–8. <a target=xrefwindow id=d8586e2136 href="http://www.ncbi.nlm.nih.gov/pubmed/23481474">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2140 href="https://doi.org/10.1097/MOP.0b013e32835d7f2c">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d8586e2149 class=n-a></a>Meinel C, Spartà G, Dahse HM, <i> et al.</i>: <i>Streptococcus pneumoniae</i> From Patients With Hemolytic Uremic Syndrome Binds Human Plasminogen via the Surface Protein PspC and Uses Plasmin to Damage Human Endothelial Cells. <i>J Infect Dis.</i> 2018; <b>217</b>(3): 358–70. <a target=xrefwindow id=d8586e2163 href="http://www.ncbi.nlm.nih.gov/pubmed/28968817">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2167 href="https://doi.org/10.1093/infdis/jix305">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d8586e2176 class=n-a></a>Coats MT, Murphy T, Paton JC, <i> et al.</i>: Exposure of Thomsen-Friedenreich antigen in <i>Streptococcus pneumoniae</i> infection is dependent on pneumococcal neuraminidase A. <i>Microb Pathog.</i> 2011; <b>50</b>(6): 343–9. <a target=xrefwindow id=d8586e2190 href="http://www.ncbi.nlm.nih.gov/pubmed/21377521">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2194 href="https://doi.org/10.1016/j.micpath.2011.02.010">Publisher Full Text </a> | <a target=xrefwindow id=d8586e2197 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3088309">Free Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d8586e2207 class=n-a></a>Banerjee R, Hersh AL, Newland J, <i> et al.</i>: <i>Streptococcus pneumoniae</i>-associated hemolytic uremic syndrome among children in North America. <i>Pediatr Infect Dis J.</i> 2011; <b>30</b>(9): 736–9. <a target=xrefwindow id=d8586e2221 href="http://www.ncbi.nlm.nih.gov/pubmed/21772230">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2225 href="https://doi.org/10.1097/INF.0b013e3182191c58">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726682327"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8586e2234 class=n-a></a>Schwartz J, Padmanabhan A, Aqui N, <i> et al.</i>: Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. <i>J Clin Apher.</i> 2016; <b>31</b>(3): 149–62. <a target=xrefwindow id=d8586e2245 href="http://www.ncbi.nlm.nih.gov/pubmed/27322218">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2248 href="https://doi.org/10.1002/jca.21470">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726682327">F1000 Recommendation</a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d8586e2261 class=n-a></a>Gilbert RD, Nagra A, Haq MR: Does dysregulated complement activation contribute to haemolytic uraemic syndrome secondary to <i>Streptococcus pneumoniae</i>? <i>Med Hypotheses.</i> 2013; <b>81</b>(3): 400–3. <a target=xrefwindow id=d8586e2272 href="http://www.ncbi.nlm.nih.gov/pubmed/23786906">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2275 href="https://doi.org/10.1016/j.mehy.2013.05.030">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d8586e2284 class=n-a></a>Brocklebank V, Kavanagh D: Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. <i>Clin Kidney J.</i> 2017; <b>10</b>(5): 600–624. <a target=xrefwindow id=d8586e2292 href="http://www.ncbi.nlm.nih.gov/pubmed/28980670">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2295 href="https://doi.org/10.1093/ckj/sfx081">Publisher Full Text </a> | <a target=xrefwindow id=d8586e2298 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5622895">Free Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d8586e2307 class=n-a></a>Gadallah MF, el-Shahawy MA, Campese VM, <i> et al.</i>: Disparate prognosis of thrombotic microangiopathy in HIV-infected patients with and without AIDS. <i>Am J Nephrol.</i> 1996; <b>16</b>(5): 446–50. <a target=xrefwindow id=d8586e2318 href="http://www.ncbi.nlm.nih.gov/pubmed/8886184">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2321 href="https://doi.org/10.1159/000169039">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d8586e2330 class=n-a></a>Becker S, Fusco G, Fusco J, <i> et al.</i>: HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study. <i>Clin Infect Dis.</i> 2004; <b>39 Suppl 5</b>: S267–75. <a target=xrefwindow id=d8586e2341 href="http://www.ncbi.nlm.nih.gov/pubmed/15494898">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2344 href="https://doi.org/10.1086/422363">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d8586e2354 class=n-a></a>Freist M, Garrouste C, Szlavik N, <i> et al.</i>: Efficacy of eculizumab in an adult patient with HIV-associated hemolytic uremic syndrome: A case report. <i>Medicine (Baltimore).</i> 2017; <b>96</b>(51): e9358. <a target=xrefwindow id=d8586e2365 href="http://www.ncbi.nlm.nih.gov/pubmed/29390523">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2368 href="https://doi.org/10.1097/MD.0000000000009358">Publisher Full Text </a> | <a target=xrefwindow id=d8586e2372 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5758225">Free Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d8586e2381 class=n-a></a>Warwicker P, Goodship TH, Donne RL, <i> et al.</i>: Genetic studies into inherited and sporadic hemolytic uremic syndrome. <i>Kidney Int.</i> 1998; <b>53</b>(4): 836–44. <a target=xrefwindow id=d8586e2392 href="http://www.ncbi.nlm.nih.gov/pubmed/9551389">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2395 href="https://doi.org/10.1111/j.1523-1755.1998.00824.x">Publisher Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d8586e2404 class=n-a></a>Challis RC, Araujo GS, Wong EK, <i> et al.</i>: A <i>De Novo</i> Deletion in the Regulators of Complement Activation Cluster Producing a Hybrid Complement Factor H/Complement Factor H-Related 3 Gene in Atypical Hemolytic Uremic Syndrome. <i>J Am Soc Nephrol.</i> 2016; <b>27</b>(6): 1617–24. <a target=xrefwindow id=d8586e2418 href="http://www.ncbi.nlm.nih.gov/pubmed/26490391">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2422 href="https://doi.org/10.1681/ASN.2015010100">Publisher Full Text </a> | <a target=xrefwindow id=d8586e2425 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4884102">Free Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d8586e2434 class=n-a></a>Goodship TH: Factor H genotype-phenotype correlations: Lessons from aHUS, MPGN II, and AMD. <i>Kidney Int.</i> 2006; <b>70</b>(1): 12–3. <a target=xrefwindow id=d8586e2442 href="http://www.ncbi.nlm.nih.gov/pubmed/16810287">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2445 href="https://doi.org/10.1038/sj.ki.5001612">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d8586e2454 class=n-a></a>Richards A, Buddles MR, Donne RL, <i> et al.</i>: Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. <i>Am J Hum Genet.</i> 2001; <b>68</b>(2): 485–90. <a target=xrefwindow id=d8586e2465 href="http://www.ncbi.nlm.nih.gov/pubmed/11170896">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2468 href="https://doi.org/10.1086/318203">Publisher Full Text </a> | <a target=xrefwindow id=d8586e2472 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1235281">Free Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d8586e2481 class=n-a></a>Kavanagh D, Kemp EJ, Mayland E, <i> et al.</i>: Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. <i>J Am Soc Nephrol.</i> 2005; <b>16</b>(7): 2150–5. <a target=xrefwindow id=d8586e2492 href="http://www.ncbi.nlm.nih.gov/pubmed/15917334">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2495 href="https://doi.org/10.1681/ASN.2005010103">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d8586e2505 class=n-a></a>Fremeaux-Bacchi V, Dragon-Durey MA, Blouin J, <i> et al.</i>: Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. <i>J Med Genet.</i> 2004; <b>41</b>(6): e84. <a target=xrefwindow id=d8586e2516 href="http://www.ncbi.nlm.nih.gov/pubmed/15173250">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2519 href="https://doi.org/10.1136/jmg.2004.019083">Publisher Full Text </a> | <a target=xrefwindow id=d8586e2523 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1735822">Free Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d8586e2532 class=n-a></a>Fremeaux-Bacchi V, Kemp EJ, Goodship JA, <i> et al.</i>: The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts. <i>J Med Genet.</i> 2005; <b>42</b>(11): 852–6. <a target=xrefwindow id=d8586e2543 href="http://www.ncbi.nlm.nih.gov/pubmed/15784724">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2546 href="https://doi.org/10.1136/jmg.2005.030783">Publisher Full Text </a> | <a target=xrefwindow id=d8586e2550 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1735946">Free Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d8586e2559 class=n-a></a>Richards A, Kemp EJ, Liszewski MK, <i> et al.</i>: Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. <i>Proc Natl Acad Sci U S A.</i> 2003; <b>100</b>(22): 12966–71. <a target=xrefwindow id=d8586e2570 href="http://www.ncbi.nlm.nih.gov/pubmed/14566051">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2573 href="https://doi.org/10.1073/pnas.2135497100">Publisher Full Text </a> | <a target=xrefwindow id=d8586e2577 href="http://www.ncbi.nlm.nih.gov/pmc/articles/240728">Free Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d8586e2586 class=n-a></a>Dragon-Durey MA, Sethi SK, Bagga A, <i> et al.</i>: Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. <i>J Am Soc Nephrol.</i> 2010; <b>21</b>(12): 2180–7. <a target=xrefwindow id=d8586e2597 href="http://www.ncbi.nlm.nih.gov/pubmed/21051740">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2600 href="https://doi.org/10.1681/ASN.2010030315">Publisher Full Text </a> | <a target=xrefwindow id=d8586e2604 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3014031">Free Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d8586e2613 class=n-a></a>Moore I, Strain L, Pappworth I, <i> et al.</i>: Association of factor H autoantibodies with deletions of <i>CFHR1</i>, <i>CFHR3</i>, <i>CFHR4</i>, and with mutations in <i>CFH</i>, <i>CFI</i>, <i>CD46</i>, and <i>C3</i> in patients with atypical hemolytic uremic syndrome. <i>Blood.</i> 2010; <b>115</b>(2): 379–87. <a target=xrefwindow id=d8586e2646 href="http://www.ncbi.nlm.nih.gov/pubmed/19861685">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2650 href="https://doi.org/10.1182/blood-2009-05-221549">Publisher Full Text </a> | <a target=xrefwindow id=d8586e2653 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2829859">Free Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d8586e2662 class=n-a></a>Frémeaux-Bacchi V, Miller EC, Liszewski MK, <i> et al.</i>: Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. <i>Blood.</i> 2008; <b>112</b>(13): 4948–52. <a target=xrefwindow id=d8586e2673 href="http://www.ncbi.nlm.nih.gov/pubmed/18796626">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2676 href="https://doi.org/10.1182/blood-2008-01-133702">Publisher Full Text </a> | <a target=xrefwindow id=d8586e2680 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2597601">Free Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1058916"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8586e2690 class=n-a></a>Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, <i> et al.</i>: Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. <i>Proc Natl Acad Sci U S A.</i> 2007; <b>104</b>(1): 240–5. <a target=xrefwindow id=d8586e2701 href="http://www.ncbi.nlm.nih.gov/pubmed/17182750">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2704 href="https://doi.org/10.1073/pnas.0603420103">Publisher Full Text </a> | <a target=xrefwindow id=d8586e2708 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1765442">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1058916">F1000 Recommendation</a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725378375"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8586e2721 class=n-a></a>Richards S, Aziz N, Bale S, <i> et al.</i>: Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. <i>Genet Med.</i> 2015; <b>17</b>(5): 405–24. <a target=xrefwindow id=d8586e2732 href="http://www.ncbi.nlm.nih.gov/pubmed/25741868">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2735 href="https://doi.org/10.1038/gim.2015.30">Publisher Full Text </a> | <a target=xrefwindow id=d8586e2739 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4544753">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725378375">F1000 Recommendation</a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d8586e2752 class=n-a></a>Esparza-Gordillo J, Goicoechea de Jorge E, Buil A, <i> et al.</i>: Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. <i>Hum Mol Genet.</i> 2005; <b>14</b>(5): 703–12. <a target=xrefwindow id=d8586e2763 href="http://www.ncbi.nlm.nih.gov/pubmed/15661753">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2766 href="https://doi.org/10.1093/hmg/ddi066">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718017565"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8586e2775 class=n-a></a>Legendre CM, Licht C, Muus P, <i> et al.</i>: Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. <i>N Engl J Med.</i> 2013; <b>368</b>(23): 2169–81. <a target=xrefwindow id=d8586e2786 href="http://www.ncbi.nlm.nih.gov/pubmed/23738544">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2789 href="https://doi.org/10.1056/NEJMoa1208981">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718017565">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d8586e2802 class=n-a></a>Licht C, Greenbaum LA, Muus P, <i> et al.</i>: Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. <i>Kidney Int.</i> 2015; <b>87</b>(5): 1061–73. <a target=xrefwindow id=d8586e2813 href="http://www.ncbi.nlm.nih.gov/pubmed/25651368">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2816 href="https://doi.org/10.1038/ki.2014.423">Publisher Full Text </a> | <a target=xrefwindow id=d8586e2820 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4424817">Free Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726911663"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8586e2829 class=n-a></a>Fakhouri F, Fila M, Provôt F, <i> et al.</i>: Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation. <i>Clin J Am Soc Nephrol.</i> 2017; <b>12</b>(1): 50–9. <a target=xrefwindow id=d8586e2840 href="http://www.ncbi.nlm.nih.gov/pubmed/27799617">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2843 href="https://doi.org/10.2215/CJN.06440616">Publisher Full Text </a> | <a target=xrefwindow id=d8586e2847 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5220663">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726911663">F1000 Recommendation</a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732086194"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8586e2861 class=n-a></a>Wijnsma KL, Duineveld C, Volokhina EB, <i> et al.</i>: Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome. <i>Nephrol Dial Transplant.</i> 2018; <b>33</b>(4): 635–45. <a target=xrefwindow id=d8586e2872 href="http://www.ncbi.nlm.nih.gov/pubmed/29106598">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2875 href="https://doi.org/10.1093/ndt/gfx196">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732086194">F1000 Recommendation</a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718321887"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8586e2888 class=n-a></a>Ardissino G, Testa S, Possenti I, <i> et al.</i>: Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. <i>Am J Kidney Dis.</i> 2014; <b>64</b>(4): 633–7. <a target=xrefwindow id=d8586e2899 href="http://www.ncbi.nlm.nih.gov/pubmed/24656451">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2902 href="https://doi.org/10.1053/j.ajkd.2014.01.434">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718321887">F1000 Recommendation</a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d8586e2915 class=n-a></a>Saland JM, Shneider BL, Bromberg JS, <i> et al.</i>: Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome. <i>Clin J Am Soc Nephrol.</i> 2009; <b>4</b>(1): 201–6. <a target=xrefwindow id=d8586e2926 href="http://www.ncbi.nlm.nih.gov/pubmed/19005013">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2929 href="https://doi.org/10.2215/CJN.02170508">Publisher Full Text </a> | <a target=xrefwindow id=d8586e2933 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2615708">Free Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/722837078"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8586e2942 class=n-a></a>Bresin E, Daina E, Noris M, <i> et al.</i>: Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. <i>Clin J Am Soc Nephrol.</i> 2006; <b>1</b>(1): 88–99. <a target=xrefwindow id=d8586e2953 href="http://www.ncbi.nlm.nih.gov/pubmed/17699195">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2956 href="https://doi.org/10.2215/CJN.00050505">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/722837078">F1000 Recommendation</a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d8586e2969 class=n-a></a>Noris M, Remuzzi G: Thrombotic microangiopathy after kidney transplantation. <i>Am J Transplant.</i> 2010; <b>10</b>(7): 1517–23. <a target=xrefwindow id=d8586e2977 href="http://www.ncbi.nlm.nih.gov/pubmed/20642678">PubMed Abstract </a> | <a target=xrefwindow id=d8586e2980 href="https://doi.org/10.1111/j.1600-6143.2010.03156.x">Publisher Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717997982"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8586e2989 class=n-a></a>Le Quintrec M, Zuber J, Moulin B, <i> et al.</i>: Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. <i>Am J Transplant.</i> 2013; <b>13</b>(3): 663–75. <a target=xrefwindow id=d8586e3000 href="http://www.ncbi.nlm.nih.gov/pubmed/23356914">PubMed Abstract </a> | <a target=xrefwindow id=d8586e3003 href="https://doi.org/10.1111/ajt.12077">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717997982">F1000 Recommendation</a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725237531"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8586e3017 class=n-a></a>Zuber J, Fakhouri F, Roumenina LT, <i> et al.</i>: Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. <i>Nat Rev Nephrol.</i> 2012; <b>8</b>(11): 643–57. <a target=xrefwindow id=d8586e3028 href="http://www.ncbi.nlm.nih.gov/pubmed/23026949">PubMed Abstract </a> | <a target=xrefwindow id=d8586e3031 href="https://doi.org/10.1038/nrneph.2012.214">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725237531">F1000 Recommendation</a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717995801"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8586e3044 class=n-a></a>Lemaire M, Frémeaux-Bacchi V, Schaefer F, <i> et al.</i>: Recessive mutations in <i>DGKE</i> cause atypical hemolytic-uremic syndrome. <i>Nat Genet.</i> 2013; <b>45</b>(5): 531–6. <a target=xrefwindow id=d8586e3058 href="http://www.ncbi.nlm.nih.gov/pubmed/23542698">PubMed Abstract </a> | <a target=xrefwindow id=d8586e3062 href="https://doi.org/10.1038/ng.2590">Publisher Full Text </a> | <a target=xrefwindow id=d8586e3065 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3719402">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717995801">F1000 Recommendation</a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717973260"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8586e3078 class=n-a></a>Ozaltin F, Li B, Rauhauser A, <i> et al.</i>: <i>DGKE</i> variants cause a glomerular microangiopathy that mimics membranoproliferative GN. <i>J Am Soc Nephrol.</i> 2013; <b>24</b>(3): 377–84. <a target=xrefwindow id=d8586e3092 href="http://www.ncbi.nlm.nih.gov/pubmed/23274426">PubMed Abstract </a> | <a target=xrefwindow id=d8586e3096 href="https://doi.org/10.1681/ASN.2012090903">Publisher Full Text </a> | <a target=xrefwindow id=d8586e3099 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3582208">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717973260">F1000 Recommendation</a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727628617"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8586e3112 class=n-a></a>Azukaitis K, Simkova E, Majid MA, <i> et al.</i>: The Phenotypic Spectrum of Nephropathies Associated with Mutations in Diacylglycerol Kinase <i>ε</i>. <i>J Am Soc Nephrol.</i> 2017; <b>28</b>(10): 3066–75. <a target=xrefwindow id=d8586e3126 href="http://www.ncbi.nlm.nih.gov/pubmed/28526779">PubMed Abstract </a> | <a target=xrefwindow id=d8586e3130 href="https://doi.org/10.1681/ASN.2017010031">Publisher Full Text </a> | <a target=xrefwindow id=d8586e3133 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5619969">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727628617">F1000 Recommendation</a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725276451"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8586e3146 class=n-a></a>Bruneau S, Néel M, Roumenina LT, <i> et al.</i>: Loss of DGKε induces endothelial cell activation and death independently of complement activation. <i>Blood.</i> 2015; <b>125</b>(6): 1038–46. <a target=xrefwindow id=d8586e3157 href="http://www.ncbi.nlm.nih.gov/pubmed/25498910">PubMed Abstract </a> | <a target=xrefwindow id=d8586e3160 href="https://doi.org/10.1182/blood-2014-06-579953">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725276451">F1000 Recommendation</a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d8586e3173 class=n-a></a>Baumgartner ER, Wick H, Linnell JC, <i> et al.</i>: Congenital defect in intracellular cobalamin metabolism resulting in homocystinuria and methylmalonic aciduria. II. Biochemical investigations. <i>Helv Paediatr Acta.</i> 1979; <b>34</b>(5): 483–96. <a target=xrefwindow id=d8586e3184 href="http://www.ncbi.nlm.nih.gov/pubmed/43301">PubMed Abstract </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726418668"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8586e3194 class=n-a></a>Beck BB, van Spronsen F, Diepstra A, <i> et al.</i>: Renal thrombotic microangiopathy in patients with cblC defect: review of an under-recognized entity. <i>Pediatr Nephrol.</i> 2017; <b>32</b>(5): 733–741. <a target=xrefwindow id=d8586e3205 href="http://www.ncbi.nlm.nih.gov/pubmed/27289364">PubMed Abstract </a> | <a target=xrefwindow id=d8586e3208 href="https://doi.org/10.1007/s00467-016-3399-0">Publisher Full Text </a> | <a target=xrefwindow id=d8586e3212 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5368212">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726418668">F1000 Recommendation</a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d8586e3225 class=n-a></a>Carrillo-Carrasco N, Chandler RJ, Venditti CP: Combined methylmalonic acidemia and homocystinuria, cblC type. I. Clinical presentations, diagnosis and management. <i>J Inherit Metab Dis.</i> 2012; <b>35</b>(1): 91–102. <a target=xrefwindow id=d8586e3233 href="http://www.ncbi.nlm.nih.gov/pubmed/21748409">PubMed Abstract </a> | <a target=xrefwindow id=d8586e3236 href="https://doi.org/10.1007/s10545-011-9364-y">Publisher Full Text </a> | <a target=xrefwindow id=d8586e3239 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4219318">Free Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d8586e3248 class=n-a></a>Cornec-Le Gall E, Delmas Y, De Parscau L, <i> et al.</i>: Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency. <i>Am J Kidney Dis.</i> 2014; <b>63</b>(1): 119–23. <a target=xrefwindow id=d8586e3259 href="http://www.ncbi.nlm.nih.gov/pubmed/24210589">PubMed Abstract </a> | <a target=xrefwindow id=d8586e3262 href="https://doi.org/10.1053/j.ajkd.2013.08.031">Publisher Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1163595"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8586e3271 class=n-a></a>Delvaeye M, Noris M, De Vriese A, <i> et al.</i>: Thrombomodulin mutations in atypical hemolytic-uremic syndrome. <i>N Engl J Med.</i> 2009; <b>361</b>(4): 345–57. <a target=xrefwindow id=d8586e3282 href="http://www.ncbi.nlm.nih.gov/pubmed/19625716">PubMed Abstract </a> | <a target=xrefwindow id=d8586e3285 href="https://doi.org/10.1056/NEJMoa0810739">Publisher Full Text </a> | <a target=xrefwindow id=d8586e3289 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3530919">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1163595">F1000 Recommendation</a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727112113"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8586e3302 class=n-a></a>Challis RC, Ring T, Xu Y, <i> et al.</i>: Thrombotic Microangiopathy in Inverted Formin 2-Mediated Renal Disease. <i>J Am Soc Nephrol.</i> 2017; <b>28</b>(4): 1084–91. <a target=xrefwindow id=d8586e3313 href="http://www.ncbi.nlm.nih.gov/pubmed/27974406">PubMed Abstract </a> | <a target=xrefwindow id=d8586e3316 href="https://doi.org/10.1681/ASN.2015101189">Publisher Full Text </a> | <a target=xrefwindow id=d8586e3320 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5373440">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727112113">F1000 Recommendation</a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735579883"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8586e3333 class=n-a></a>Le Clech A, Simon-Tillaux N, Provôt F, <i> et al.</i>: Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors. <i>Kidney Int.</i> 2019; <b>95</b>(6): 1443–52. <a target=xrefwindow id=d8586e3344 href="http://www.ncbi.nlm.nih.gov/pubmed/30982675">PubMed Abstract </a> | <a target=xrefwindow id=d8586e3347 href="https://doi.org/10.1016/j.kint.2019.01.023">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735579883">F1000 Recommendation</a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733084692"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8586e3361 class=n-a></a>Gupta M, Feinberg BB, Burwick RM: Thrombotic microangiopathies of pregnancy: Differential diagnosis. <i>Pregnancy Hypertens.</i> 2018; <b>12</b>: 29–34. <a target=xrefwindow id=d8586e3369 href="http://www.ncbi.nlm.nih.gov/pubmed/29674195">PubMed Abstract </a> | <a target=xrefwindow id=d8586e3372 href="https://doi.org/10.1016/j.preghy.2018.02.007">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733084692">F1000 Recommendation</a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727698015"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8586e3385 class=n-a></a>Bruel A, Kavanagh D, Noris M, <i> et al.</i>: Hemolytic Uremic Syndrome in Pregnancy and Postpartum. <i>Clin J Am Soc Nephrol.</i> 2017; <b>12</b>(8): 1237–47. <a target=xrefwindow id=d8586e3396 href="http://www.ncbi.nlm.nih.gov/pubmed/28596415">PubMed Abstract </a> | <a target=xrefwindow id=d8586e3399 href="https://doi.org/10.2215/CJN.00280117">Publisher Full Text </a> | <a target=xrefwindow id=d8586e3403 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5544502">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727698015">F1000 Recommendation</a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/4022956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8586e3416 class=n-a></a>Fakhouri F, Roumenina L, Provot F, <i> et al.</i>: Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. <i>J Am Soc Nephrol.</i> 2010; <b>21</b>(5): 859–67. <a target=xrefwindow id=d8586e3427 href="http://www.ncbi.nlm.nih.gov/pubmed/20203157">PubMed Abstract </a> | <a target=xrefwindow id=d8586e3430 href="https://doi.org/10.1681/ASN.2009070706">Publisher Full Text </a> | <a target=xrefwindow id=d8586e3434 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2865741">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/4022956">F1000 Recommendation</a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d8586e3446 class=n-a></a>Ardissino G, Wally Ossola M, Baffero GM, <i> et al.</i>: Eculizumab for atypical hemolytic uremic syndrome in pregnancy. <i>Obstet Gynecol.</i> 2013; <b>122</b>(2 Pt 2): 487–9. <a target=xrefwindow id=d8586e3457 href="http://www.ncbi.nlm.nih.gov/pubmed/23884270">PubMed Abstract </a> | <a target=xrefwindow id=d8586e3460 href="https://doi.org/10.1097/AOG.0b013e31828e2612">Publisher Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735366940"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8586e3469 class=n-a></a>El Karoui K, Boudhabhay I, Petitprez F, <i> et al.</i>: Impact of hypertensive emergency and complement rare variants on presentation and outcome of atypical hemolytic uremic syndrome. <i>Haematologica.</i> 2019; pii: haematol.2019.216903. <a target=xrefwindow id=d8586e3477 href="http://www.ncbi.nlm.nih.gov/pubmed/30890598">PubMed Abstract </a> | <a target=xrefwindow id=d8586e3480 href="https://doi.org/10.3324/haematol.2019.216903">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735366940">F1000 Recommendation</a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d8586e3493 class=n-a></a>Izzedine H, Perazella MA: Thrombotic microangiopathy, cancer, and cancer drugs. <i>Am J Kidney Dis.</i> 2015; <b>66</b>(5): 857–68. <a target=xrefwindow id=d8586e3501 href="http://www.ncbi.nlm.nih.gov/pubmed/25943718">PubMed Abstract </a> | <a target=xrefwindow id=d8586e3504 href="https://doi.org/10.1053/j.ajkd.2015.02.340">Publisher Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726771118"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8586e3514 class=n-a></a>Kavanagh D, McGlasson S, Jury A, <i> et al.</i>: Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature. <i>Blood.</i> 2016; <b>128</b>(24): 2824–33. <a target=xrefwindow id=d8586e3525 href="http://www.ncbi.nlm.nih.gov/pubmed/27663672">PubMed Abstract </a> | <a target=xrefwindow id=d8586e3528 href="https://doi.org/10.1182/blood-2016-05-715987">Publisher Full Text </a> | <a target=xrefwindow id=d8586e3532 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5159705">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726771118">F1000 Recommendation</a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1104316"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8586e3545 class=n-a></a>Eremina V, Jefferson JA, Kowalewska J, <i> et al.</i>: VEGF Inhibition and Renal Thrombotic Microangiopathy. <i>N Engl J Med.</i> 2008; <b>358</b>(11): 1129–36. <a target=xrefwindow id=d8586e3556 href="http://www.ncbi.nlm.nih.gov/pubmed/18337603">PubMed Abstract </a> | <a target=xrefwindow id=d8586e3559 href="https://doi.org/10.1056/NEJMoa0707330">Publisher Full Text </a> | <a target=xrefwindow id=d8586e3563 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3030578">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1104316">F1000 Recommendation</a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d8586e3576 class=n-a></a>Zakarija A, Bandarenko N, Pandey DK, <i> et al.</i>: Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. <i>Stroke.</i> 2004; <b>35</b>(2): 533–7. <a target=xrefwindow id=d8586e3587 href="http://www.ncbi.nlm.nih.gov/pubmed/14707231">PubMed Abstract </a> | <a target=xrefwindow id=d8586e3590 href="https://doi.org/10.1161/01.STR.0000109253.66918.5E">Publisher Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d8586e3599 class=n-a></a>Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, <i> et al.</i>: Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. <i>Ann Intern Med.</i> 1998; <b>128</b>(7): 541–4. <a target=xrefwindow id=d8586e3610 href="http://www.ncbi.nlm.nih.gov/pubmed/9518398">PubMed Abstract </a> | <a target=xrefwindow id=d8586e3613 href="https://doi.org/10.7326/0003-4819-128-7-199804010-00004">Publisher Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d8586e3622 class=n-a></a>Morton JM, George JN: Microangiopathic Hemolytic Anemia and Thrombocytopenia in Patients With Cancer. <i>J Oncol Pract.</i> 2016; <b>12</b>(6): 523–30. <a target=xrefwindow id=d8586e3630 href="http://www.ncbi.nlm.nih.gov/pubmed/27288467">PubMed Abstract </a> | <a target=xrefwindow id=d8586e3633 href="https://doi.org/10.1200/JOP.2016.012096">Publisher Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d8586e3642 class=n-a></a>Jodele S, Licht C, Goebel J, <i> et al.</i>: Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. <i>Blood.</i> 2013; <b>122</b>(12): 2003–7. <a target=xrefwindow id=d8586e3653 href="http://www.ncbi.nlm.nih.gov/pubmed/23814021">PubMed Abstract </a> | <a target=xrefwindow id=d8586e3656 href="https://doi.org/10.1182/blood-2013-05-501445">Publisher Full Text </a> | <a target=xrefwindow id=d8586e3660 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3790943">Free Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d8586e3670 class=n-a></a>Jodele S, Fukuda T, Vinks A, <i> et al.</i>: Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. <i>Biol Blood Marrow Transplant.</i> 2014; <b>20</b>(4): 518–25. <a target=xrefwindow id=d8586e3681 href="http://www.ncbi.nlm.nih.gov/pubmed/24370861">PubMed Abstract </a> | <a target=xrefwindow id=d8586e3684 href="https://doi.org/10.1016/j.bbmt.2013.12.565">Publisher Full Text </a> | <a target=xrefwindow id=d8586e3688 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5436705">Free Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d8586e3697 class=n-a></a>de Fontbrune FS, Galambrun C, Sirvent A, <i> et al.</i>: Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC. <i>Transplantation.</i> 2015; <b>99</b>(9): 1953–9. <a target=xrefwindow id=d8586e3708 href="http://www.ncbi.nlm.nih.gov/pubmed/25651309">PubMed Abstract </a> | <a target=xrefwindow id=d8586e3711 href="https://doi.org/10.1097/TP.0000000000000601">Publisher Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d8586e3720 class=n-a></a>Le Quintrec M, Lionet A, Kamar N, <i> et al.</i>: Complement mutation-associated <i>de novo</i> thrombotic microangiopathy following kidney transplantation. <i>Am J Transplant.</i> 2008; <b>8</b>(8): 1694–701. <a target=xrefwindow id=d8586e3734 href="http://www.ncbi.nlm.nih.gov/pubmed/18557729">PubMed Abstract </a> | <a target=xrefwindow id=d8586e3738 href="https://doi.org/10.1111/j.1600-6143.2008.02297.x">Publisher Full Text </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/728379383"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8586e3747 class=n-a></a>Ankawi GA, Clark WF: Atypical haemolytic uremic syndrome (aHUS) and membranoproliferative glomerulonephritis (MPGN), different diseases or a spectrum of complement-mediated glomerular diseases? <i>BMJ Case Rep.</i> 2017; <b>2017</b>: pii: bcr-2017-220974. <a target=xrefwindow id=d8586e3755 href="http://www.ncbi.nlm.nih.gov/pubmed/28798244">PubMed Abstract </a> | <a target=xrefwindow id=d8586e3758 href="https://doi.org/10.1136/bcr-2017-220974">Publisher Full Text </a> | <a target=xrefwindow id=d8586e3761 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5624031">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/728379383">F1000 Recommendation</a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d8586e3774 class=n-a></a>Barratt-Due A, Fløisand Y, Orrem HL, <i> et al.</i>: Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome. <i>Rheumatology (Oxford).</i> 2016; <b>55</b>(7): 1337–9. <a target=xrefwindow id=d8586e3785 href="http://www.ncbi.nlm.nih.gov/pubmed/27105662">PubMed Abstract </a> | <a target=xrefwindow id=d8586e3788 href="https://doi.org/10.1093/rheumatology/kew040">Publisher Full Text </a> | <a target=xrefwindow id=d8586e3792 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4911539">Free Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 25 Sep 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-1690&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-1690&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> National Renal Complement Therapeutics Centre, Institute of Cellular Medicine, Newcastle University and Biomedical Research Centre, Newcastle-upon-Tyne NHS Foundation Trust, Newcastle-upon-Tyne, UK<br/> <p> <div class=margin-bottom> Neil S. Sheerin <br/> <span>Roles: </span> Writing – Original Draft Preparation </div> <div class=margin-bottom> Emily Glover <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/8-1690/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 25 Sep 2019, 8:1690 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.19957.1">https://doi.org/10.12688/f1000research.19957.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2019 Sheerin NS and Glover E. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=21904 data-id=19957 data-downloads="" data-views="" data-scholar="10.12688/f1000research.19957.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/8-1690/v1/pdf?article_uuid=75be1393-3997-4d5a-a78a-06b4278e6777" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.19957.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Sheerin NS and Glover E. Haemolytic uremic syndrome: diagnosis and management [version 1; peer review: 3 approved] <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1690 (<a href="https://doi.org/10.12688/f1000research.19957.1" target=_blank>https://doi.org/10.12688/f1000research.19957.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=19957 id=mobile-track-article-signin-19957 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/19957?target=/articles/8-1690"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=21904 /> <input name=articleId type=hidden value=19957 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Chantal Loirat</strong>, Université de Paris, Hôpital Universitaire Robert Debré, Assistance Publique-Hôpitaux de Paris, France </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Richard Coward</strong>, Bristol Medical School, University of Bristol, UK </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Aoife Waters</strong>, University College London, Great Ormond Street Institute of Child Health, UK </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 25 Sep 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-1690&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-1690&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=57330-54342></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=57331-54343></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=57329-54344></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/8-1690/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>25 Sep 19</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Chantal Loirat</strong>, Université de Paris, Hôpital Universitaire Robert Debré, Assistance Publique-Hôpitaux de Paris, France </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Richard Coward</strong>, Bristol Medical School, University of Bristol, UK </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Aoife Waters</strong>, University College London, Great Ormond Street Institute of Child Health, UK </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/8-1690&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/8-1690/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Haemolytic uremic syndrome: diagnosis and...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/8-1690/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/8-1690/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/8-1690/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Sheerin NS and Glover E');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/8-1690/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/8-1690",
            templates : {
                twitter : "Haemolytic uremic syndrome: diagnosis and management. Sheerin NS and Glover E, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/8-1690/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Haemolytic uremic syndrome: diagnosis and management", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Haemolytic uremic syndrome: diagnosis and management", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/19957/21904")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "21904");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "54342": 1,
                           "54343": 0,
                           "54344": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "ab12146e-9687-4311-8f2c-356c302a92b8";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1690.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1690.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1690.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/8-1690.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/8-1690.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>